Abstract
ISM, primarily driven by the KIT D816V mutation, is the most frequent systemic mastocytosis subtype which may cause debilitating symptoms. PIONEER (NCT03731260) assessed safety and efficacy of avapritinib, an investigational selective KIT D816V inhibitor, vs placebo, both with best supportive care (BSC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
